<unk>  is a leprostatic that is FDA approved for the treatment of newly diagnosed multiple myeloma in combination with dexamethasone and cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, hypocalcemia, edema, constipation, sensory neuropathy, dyspnea, muscle weakness, leukopenia, neutropenia, rash/desquamation, confusion, anorexia, nausea, anxiety/agitation, asthenia, tremor, fever, weight loss, thrombosis/embolism, motor neuropathy, weight gain, dizziness, and dry skin.
Thalidomide
Pomalidomide
Lenalidomide
Hydroxyurea
Mafosfamide
Vincristine sulfate
Mercaptopurine
Febuxostat